Equillium (EQ) Expected to Announce Earnings on Thursday

Equillium (NASDAQ:EQ) is projected to issue its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 23, 2026 at 12:30 PM ET.

Equillium Trading Down 0.9%

Shares of Equillium stock opened at $2.13 on Thursday. Equillium has a twelve month low of $0.27 and a twelve month high of $2.70. The stock has a market cap of $129.70 million, a price-to-earnings ratio of -3.44 and a beta of 1.81. The company has a fifty day moving average price of $1.59 and a 200 day moving average price of $1.42.

Analyst Upgrades and Downgrades

EQ has been the topic of a number of recent research reports. Wall Street Zen raised Equillium from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Roth Mkm initiated coverage on Equillium in a report on Friday, March 13th. They set a “buy” rating and a $12.00 target price on the stock. Stifel Nicolaus started coverage on Equillium in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a report on Monday, December 29th. Finally, Zacks Research raised shares of Equillium to a “hold” rating in a research report on Thursday, February 26th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Equillium has a consensus rating of “Hold” and a consensus target price of $6.00.

Insider Buying and Selling at Equillium

In other news, COO Christine Zedelmayer sold 120,312 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $2.50, for a total transaction of $300,780.00. Following the completion of the sale, the chief operating officer directly owned 62,586 shares in the company, valued at $156,465. This trade represents a 65.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 594,001 shares of company stock worth $1,148,895 in the last three months. 31.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of EQ. ADAR1 Capital Management LLC grew its stake in Equillium by 0.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 5,608,078 shares of the company’s stock valued at $8,693,000 after purchasing an additional 48,090 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Equillium in the 4th quarter valued at approximately $9,057,000. Balyasny Asset Management L.P. boosted its stake in shares of Equillium by 3.6% during the 4th quarter. Balyasny Asset Management L.P. now owns 2,076,250 shares of the company’s stock valued at $3,218,000 after buying an additional 72,602 shares during the last quarter. Cantor Fitzgerald L. P. grew its position in shares of Equillium by 32.4% during the fourth quarter. Cantor Fitzgerald L. P. now owns 562,643 shares of the company’s stock worth $872,000 after buying an additional 137,643 shares in the last quarter. Finally, Diadema Partners LP grew its position in shares of Equillium by 15.8% during the fourth quarter. Diadema Partners LP now owns 347,393 shares of the company’s stock worth $538,000 after buying an additional 47,393 shares in the last quarter. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.